Auditory monitoring in ototoxicity

Brazilian Journal of Otorhinolaryngology

Volumn 72, Issue 6, 2006, Pages 836-844

  Jacob, Lilian Cassia Bornia ^a,b,c   Aguiar, Fabrina Pavia ^b   Tomiasi, Aline Aparecida ^b   Tschoeke, Samira Natacha ^b   De Bitencourt, Raquel Fava ^b  

^a Speech and Hearing Therapy School   (Brazil)

^b UNIVERSIDADE TUIUTI DO PARANÁ   (Brazil)

^c Tuiuti University of Paraná ^*  (Brazil)

Author keywords

Hearing loss; Medication; Monitoring; Neoplasms

Indexed keywords

6 AMINONICOTINAMIDE; AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIFUNGAL AGENT; CAPREOMYCIN; CHLORAMPHENICOL; CISPLATIN; COLISTIN; ERYTHROMYCIN; ETACRYNIC ACID; FUROSEMIDE; GENTAMICIN; GRISEOFULVIN; KANAMYCIN; MINOCYCLINE; MISONIDAZOLE; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMYXIN B; QUININE; SALICYLIC ACID; STREPTOMYCIN; VANCOMYCIN; VINCRISTINE;

AUDIOMETRY; DATA BASE; EAR CANCER; HEARING ACUITY; HEARING DISORDER; HUMAN; MEDICAL LITERATURE; MEDLINE; OTOTOXICITY; REVIEW;

EID: 33846563552     PISSN: 18088694     EISSN: 18088686     Source Type: Journal    
DOI: 10.1016/S1808-8694(15)31053-3     Document Type: Review

References (50)

1. Oliveira JAA, Canedo DM, Rossato M. Otoproteçäo das células ciliadas auditivas contra a ototoxicidade da amicacina. Rev Bras Otorrinolaringol 2002;68(1):7-13.
2. Alvarenga KF, Jacob LCB, Martins CHF, Costa AO, Coube CZV, Marques JM. Emissöes otoacústicas - produto de distorçäo em indivíduos expostos ao chumbo e ao ruído. Rev Bras Otorrinolaringol 2003;69 (5):681-6.
3. Morata TC. Chemical exposure as a risk factor for hearing loss. J Occup Environ Med 2003;45(7):676-82.
4. Teixeira CF, Augusto LG, Morata TC. Saúde auditiva de trabalhadores expostos a ruído e inseticidas. Rev Saúde Publica 2003;37(4):417-23.
5. Berg AL, Spitzer JB, Garvin JH Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 1999;109(11):1806-14.
6. Dishtchekenian A, Iorio MCM, Petrilli AS, Azevedo MF. Monitorização auditiva na ototoxicidade In: Barros A et al. Fonoaudiologia em Cancerologia, São Paulo, Fundação Oncocentro, 2000b, 260-269.
7. Dishtchekenian A, Iorio MCM, Petrilli AS, Paiva ER, Azevedo MF. Acompanhamento audiológico em pacientes com osteossarcoma submetidos à quimioterapia com cisplatina. Rev Bras Otorrinolaringol 2000;66 (6):580-90.
8. Ozturan O, Jerger J, Lew H, Lynch GR. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx 1996;23:147-51.
9. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions - an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 2001;31,59(1):47-57.
10. Testa JRG. Aspectos otológicos do paciente com câncer de cabeça e pescoço. In: De Angelis EC, Ferreira CLB, Kowalski LP. A atuação da fonoaudiologia no câncer de cabeça e pescoço, São Paulo: Lovise; 2000. p.135-8.
11. Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. Early detection of cisplatin ototoxicity. Selected case reports. Cancer 1984;15,53(2):224-31.
12. Aguiar F. A influência de medicamentos nas funções auditiva e vestibular. Curitiba, 2000, (monografia de conclusão de curso - Universidade Tuiuti do Paraná).
13. Moussalle MM, Rangel M, Baú ALW, Stangler S, Gomes NHG, Moussalle S. Prevenção e abordagem do uso de drogas ototóxicas. Acta Méd 1997;(1):100-8.
14. Mckeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13(4):228-44.
15. Pasic TR, Dobie RA. Cis-platinum ototoxicity in children. Laryngoscope 1991;101(9):985-91.
16. Fausti SA, Frey RH, Henry JA, Olson J, Schaffer HI. High-frequency testing techniques and instrumentation for early detection of ototoxicity. Journal Rehabilitation Res Development 1993;30 (3):333-41.
17. Fausti SA, Henry JA, Helt WJ, Phillips DS, Frey RH, Noffsinger D et al. An Individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear 1999;20(6):497-505.
18. Garcia AP, Iório MCM, Petrilli AS. Monitoramento da audição de pacientes expostos à cisplatina. Rev Bras Otorrinolaringol 2003;69(2):215-21.
19. Oliveira JAA. Ototoxidade. In: Costa SS, Cruz OLM, Oliveira JAA et al. Otorrinolaringologia: Princípios e Prática. Porto Alegre: Artes Médicas; 1994.
20. Park KR. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population. Ear Hear 1996;17(2):107-15.
21. Littman TA, Magruder A, Strother DR. Monitoring and predicting ototoxic damage using distortion-product otoacustic emissions: pediatric case study. J Am Acad Audiol 1998;9(4):257-62.
22. Yardley MP, Davies CM, Stevens JC. Use of Transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum- containing drugs. Br J Audiol 1998;32(5):305-16.
23. Borges GC, Borges RHM, Baraúna GN, Filho OL. Ototoxicidade Causada pela Cisplatina em Crianças. Estudo Retrospectivo. Rev Bras Otorrinolaringol 2001;67(3):292-5.
24. Penido NO, Mota PHM, Mascari DSA, Fukuda Y. Ototoxicidade induzida por cis-diamminedichloroplatinum (NSC - 119875). Acta Awho 1989;(8):80-3.
25. American Speech-Language-Hearing Association audiologic management of individuals receiving cochleotoxic drug therapy. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA, 1994;36(suppl. 12):11-9.
26. Cevette MJ, Drew D, Webb TM, Marion MS. Cisplatin ototoxicity, increased DPOAE amplitudes, and magnesium deficiency. Distortion product otoacoustic emissions. J Am Acad Audiol 2000;11(6):323-9.
27. De Lauretis A, De Capua B, Barbieri MT, Bellussi L, Passàli D. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol 1999;28(3):139-43.
28. Fausti SA, Frey RH, Henry JA, Olson J, Schaffer HI. Early detection of ototoxicity using high-frequency, tone burst-evoked auditory brainsteam responses. J Am Acad Audiol 1992;3(6):397-404.
29. Dreschler WA, Van Der Hulst RJ, Tange RA, Urbanus NA. Role of high-Frequency Audiometry in early detection of ototoxicity. Audiology 1989;28(4):211-20.
30. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear 1994;15(3):232-9.
31. Feghali JG, Bernstein RS. A new approach to serial monitoring of ultra-high frequency hearing. Laryngoscope 1991;101(8):825-9.
32. Tange RA, Dreschler WA, Van Der Hulst RJ. The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 1985;242(1):77-81.
33. Zeigelboim BS, Mangabeira-Albernaz PL, Fukuda Y. Audiometria de Altas Freqüências: Monitoramento Auditivo. Temas em ORL & Cirurgia de Cabeça e Pescoço 2001;2:21-25.
34. Simpson TH, Schwan SA, Rintelmann WF. Audiometric test criteria in the detection of cisplatin ototoxicity. J Am Acad Audiol 1992;3(3):176-85.
35. Kemp DT. Evidence of mechanical nonlinearity and frequency selective wave amplification in the coclear. Arch Otorhinolaryngol 1979;224(1-2):37-45.
36. Prosbt R, Coats A, Martin G, Lonsbury-Martin B. Spontaneous, click a tone burst-evoked emissions from normal ears. Hear Res 1986;21(3):261-75.
37. Desai A, Reed D, Cheyne A, Reichards S, Prasher D. Absence of otoacoustic emissions in subjects with normal audiometric thresholds implies exposure to noise. Noise Health 1999;1(2):58-65.
38. Prasher D, Sulkowski W. The role of otoacoustic emissions in screening and evaluation of noise damage. Internat J Occup Med Environ Health 1999;12(2):183-92.
39. Beck A, Maurer J, Welkoborsky HJ, Mann W. Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU. HNO 1992;40(4):123-7.
40. Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope 1994;104(9):1130-4.
41. Orts Alborch M, Morant Ventura A, Garcia Callejo J, Ferrer Baixauli F, Martinez Beneito MP, Marco Algarra J. Monitoring drug ototoxicity with distortion products. Acta Otorrinolaringol Esp 2000;1(5):387-95.
42. Plinkert PK, Kröber S. Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions. Laryngorhinootologie 1991;70(9):457-62.
43. Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, Douniadakis D. Otoacoustic emissions - an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999;50(3):177-84.
44. Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg 2002;128(2):150-5.
45. Vallejo JC, Silva MN, Oliveira JAA, Carneiro JJ, Rocha LSO, Figueiredo JFC et al. Detecção precoce de ototoxicidade usando emissões otoacústicas produtivas de distorção. Rev Bras Otorrinolaringol 2001;67 (6):845-51.
46. Zorowka PG, Schmitt HJ, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. Int J Pediatr Otorhinolaryngol 1993;25(1-3):73-80.
47. Paz I, Codjambassis D, Pinto U. Emissiones Otoacústicas en la Detección Precoz de Ototoxicidad Inducida por Cisplatino. Rev Otorrinolaringol CIR Cabeza Cuello 2000;(60):7-13.
48. Jacob LCB, Stumpf CC, Bitencourt RF, Marques JM, Puppi C, Gonçalves PT. Avaliação audiológica em indivíduos com neoplasias expostos a agentes quimioterápicos. Fono Atual 2005;3:12-25.
49. Santos CF, Valete CM, Martins AG, Ferreira NGM, Tomita S. Aspectos clínicos da ototoxicidade dos aminoglicosídeos. Acta Awho 2000;19(3):160-4.
50. Mulheran M, Degg C. Comparison of distortion product OAE generation between a patient growth requirent frequent gentamicin therapy and control subjects. Br J Audiol 1997;31(1):5-9.